surpass cvot tirzepatide SURPASS-CVOT Shows Mounjaro Surpasses Trulicity in CV Outcomes Should Diabetes Management be More

Comparing Cagrilintide with GLP-1 receptor agonists allows researchers to examine how different peptide hormone pathways influence metabolic signaling, receptor pharmacology, and neuroendocrine regulatory mechanisms

Cavaliere G, Trinchese G, Penna E, Cimmino F, Pirozzi C, Lama A, et al

The compounding issue and preventing poor practices The presentation from Zach Zalewski, Strategic Director at the United States Pharmacopeia, focused on compounding primarily regulatory policies, litigation and drug quality issues

Our providers will order and draw them

Article PubMed CAS Google Scholar Shirotani, M., Suwa, T., Kurokawa, T

Clinical evidence from the STEP trials demonstrated that participants on semaglutide lost significantly more weight than those on placebo, with benefits sustained over 2+ years of continuous therapy